| Abstract | AIM: In the present study we report the clinical outcome of 27 patients with refractory or relapsed Hodgkin's lymphoma (HL) undergoing autologous peripheral stem-cell transplantation (ASCT). METHODS: On transplant, 18 patients had sensitive disease (SD) and 9 resistant disease (RD). The median time between diagnosis and ASCT was 18 months (range, 7 to 96 months). The conditioning consisted of BEAM regimen. RESULTS: The 100-day mortality rate was 3%. Three months after transplant, 12 patients transplanted with SD were in complete remission (CR) and only one of the 9 patients transplanted with RD achieved CR. Overall survival and disease-free survival after 3 years were 68% and 60%, respectively. CONCLUSION: the present results confirm the efficacy and safety of the ASCT in refractory or relapsed HL patients with SD. Other strategies should be investigated for patients with RD. |
| Authors | Lamia Torjman, Saloua Ladeb, Amel Lakhal, Tarek Ben Othman, Abderrahman Abdelkefi, Abdeladhim Ben Abdeladhim
(Affiliation: Centre National de Greffe de Moelle Osseuse, Tunis.)
|
| Journal | La Tunisie médicale
(Tunis Med)
Vol. 85
Issue 1
Pg. 35-8
(Jan 2007)
ISSN: 0041-4131 Tunisia |
| PMID | 17424707
(Publication Type: Comparative Study, Journal Article)
|
| Chemical References |
- Antineoplastic Agents
- BEAM regimen
- Cytarabine
- Melphalan
- Carmustine
- Etoposide
|
| Topics |
- Adolescent
- Adult
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Carmustine
(administration & dosage, therapeutic use)
- Child
- Cytarabine
(administration & dosage, therapeutic use)
- Data Interpretation, Statistical
- Disease-Free Survival
- Drug Resistance, Neoplasm
- Etoposide
(administration & dosage, therapeutic use)
- Follow-Up Studies
- Hodgkin Disease
(drug therapy, mortality, pathology, therapy)
- Humans
- Melphalan
(administration & dosage, therapeutic use)
- Neoplasm Staging
- Peripheral Blood Stem Cell Transplantation
(adverse effects)
- Recurrence
- Remission Induction
- Time Factors
- Transplantation Conditioning
- Transplantation, Autologous
- Treatment Outcome
|
